Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Bone marrow micrometastases do not impact disease-free and overall survival in early stage sentinel lymph node-negative breast cancer patients
Langer I, Zuber M, Koechli O, Burger D, Infanger E, Wight E, Schnarwyler B, Bronz L, Viehl C, Hess T, Fehr M, Schaer G, Singer G, Berclaz G, Worni M, Gueller U, Swiss Multicenter Sentinel Lymph Node Study Group in Breast Cancer. Bone marrow micrometastases do not impact disease-free and overall survival in early stage sentinel lymph node-negative breast cancer patients. Ann Surg Oncol 2013; 21:401-7.
22.10.2013Bone marrow micrometastases do not impact disease-free and overall survival in early stage sentinel lymph node-negative breast cancer patients
22.10.2013Ann Surg Oncol 2013; 21:401-7
Langer Igor, Zuber Markus, Koechli Ossi R, Burger Daniel, Infanger Eduard, Wight Edward, Schnarwyler Beate, Bronz Lucio, Viehl Carsten, Hess Thomas, Fehr Mathias K, Schaer Gabriel, Singer Gad, Berclaz Gilles, Worni Mathias, Gueller Ulrich, Swiss Multicenter Sentinel Lymph Node Study Group in Breast Cancer
Medizinisches Handeln zwischen Himmel und Erde
Renz M (2013). Medizinisches Handeln zwischen Himmel und Erde - Wie fallen Entscheidungen an den Nahtstellen des Lebens von Geburt und Tod. Präsentiert bei: "Entscheiden": der Mensch denkt und Gott lenkt!?, -
21.10.2013Medizinisches Handeln zwischen Himmel und Erde
21.10.2013"Entscheiden": der Mensch denkt und Gott lenkt!?
Renz Monika
Local Renin-Angiotensin system in the reproductive system
Herr D, Bekes I, Wulff C. Local Renin-Angiotensin system in the reproductive system. Front Endocrinol (Lausanne) 2013; 4:150.
18.10.2013Local Renin-Angiotensin system in the reproductive system
18.10.2013Front Endocrinol (Lausanne) 2013; 4:150
Herr Daniel, Bekes Inga, Wulff Christine
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
Gerber B, Jackisch C, Kunz G, Blohmer J, Huober J, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, Solbach C, Kreienberg R, Hanusch C, Loibl S, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, German Breast Group Investigators. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 2013; 24:2978-84.
17.10.2013Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
17.10.2013Ann Oncol 2013; 24:2978-84
Gerber B, Jackisch C, Kunz G, Blohmer J U, Huober Jens, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, Solbach C, Kreienberg R, Hanusch C, Loibl S, Eidtmann H, Rezai M, Fasching P A, Tesch H, Eggemann H, Schrader I, Kittel K, German Breast Group Investigators
Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial
Banys M, Wallwiener D, Hirnle P, Wackwitz B, Kraemer B, Huober J, Becker S, Lueck H, Krawczyk N, Janni W, Gebauer G, Solomayer E, Fehm T. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC cancer 2013; 13:480.
15.10.2013Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial
15.10.2013BMC cancer 2013; 13:480
Banys Malgorzata, Wallwiener Diethelm, Hirnle Peter, Wackwitz Birgit, Kraemer Bernhard, Huober Jens, Becker Sven, Lueck Hans-Joachim, Krawczyk Natalia, Janni Wolfgang, Gebauer Gerhard, Solomayer Erich-Franz, Fehm Tanja
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials
Templeton A, Amir E, Pond G, Joshua A, Sridhar S, Moore M, Knox J, Leibowitz-Amit R, De Gouveia P, Attalla M, Wang L, Vera-Badillo F, Tannock I. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24:2972-7.
14.10.2013Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials
14.10.2013Ann Oncol 2013; 24:2972-7
Templeton Arnoud, Amir E, Pond G R, Joshua A M, Sridhar S S, Moore M, Knox J J, Leibowitz-Amit R, De Gouveia P, Attalla M, Wang L, Vera-Badillo F E, Tannock I F
Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients
Hilvo M, Orešič M, Denkert C, von Minckwitz G, Huober J, Untch M, Sysi-Aho M, Seppänen-Laakso T, Nekljudova V, Hyötyläinen T, Gade S, Loibl S. Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 2013; 134:1725-33.
08.10.2013Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients
08.10.2013Int J Cancer 2013; 134:1725-33
Hilvo Mika, Orešič Matej, Denkert Carsten, von Minckwitz Gunter, Huober Jens, Untch Michael, Sysi-Aho Marko, Seppänen-Laakso Tuulikki, Nekljudova Valentina, Hyötyläinen Tuulia, Gade Stephan, Loibl Sibylle
Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008
Worni M, Gueller U, White R, Castleberry A, Pietrobon R, Cerny T, Gloor B, Koeberle D. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas 2013; 42:1157-63.
01.10.2013Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008
01.10.2013Pancreas 2013; 42:1157-63
Worni Mathias, Gueller Ulrich, White Rebekah R, Castleberry Anthony W, Pietrobon Ricardo, Cerny Thomas, Gloor Beat, Koeberle Dieter
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
Bianchini D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin A, Rodriguez-Vida A, Lorente D, de Bono J. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 2013; 50:78-84.
25.09.2013Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
25.09.2013Eur J Cancer 2013; 50:78-84
Bianchini D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin Aurelius, Rodriguez-Vida A, Lorente D, de Bono J S
Endobronchial ultrasound-guided transbronchial needle aspiration of an intravascular sarcoma metastasis
Dusemund F, Schneider T, Zeisel C, Rothermundt C, Kluckert T, Schmid S, Brutsche M. Endobronchial ultrasound-guided transbronchial needle aspiration of an intravascular sarcoma metastasis. Respiration 2013; 86:430-432.
24.09.2013Endobronchial ultrasound-guided transbronchial needle aspiration of an intravascular sarcoma metastasis
24.09.2013Respiration 2013; 86:430-432
Dusemund Frank, Schneider Tino, Zeisel Christoph, Rothermundt Christian, Kluckert Thomas, Schmid Sabine, Brutsche Martin
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study
Terwijn M, Graux C, Bargetzi M, Legdeur M, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck L, Gratama J, Oussoren Y, Scholten W, Slomp J, Snel A, Vekemans M, Löwenberg B, Ossenkoppele G, Wijermans P, van Gelder M, van Putten W, Kelder A, van der Velden V, Brooimans R, Pabst T, Maertens J, Boeckx N, de Greef G, Valk P, Preijers F, Huijgens P, Dräger A, Schanz U, Jongen-Lavrecic M, Biemond B, Passweg J, Schuurhuis G. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013; 31:3889-97.
23.09.2013High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study
23.09.2013J Clin Oncol 2013; 31:3889-97
Terwijn Monique, Graux Carlos, Bargetzi Mario, Legdeur Marie-Cecile, Kuball Jurgen, de Weerdt Okke, Chalandon Yves, Hess Urs, Verdonck Leo F, Gratama Jan W, Oussoren Yvonne J M, Scholten Willemijn J, Slomp Jennita, Snel Alexander N, Vekemans Marie-Christiane, Löwenberg Bob, Ossenkoppele Gert J, Wijermans Pierre, van Gelder Michel, van Putten Wim L J, Kelder Angèle, van der Velden Vincent H J, Brooimans Rik A, Pabst Thomas, Maertens Johan, Boeckx Nancy, de Greef Georgine E, Valk Peter J M, Preijers Frank W M B, Huijgens Peter C, Dräger Angelika M, Schanz Urs, Jongen-Lavrecic Mojca, Biemond Bart J, Passweg Jakob R, Schuurhuis Gerrit J
Management of patients with castration-resistant disease
Pezaro C, Omlin A, Lorente D, de Bono J. Management of patients with castration-resistant disease. Hematol Oncol Clin North Am 2013; 27:1243-60, ix.
20.09.2013Management of patients with castration-resistant disease
20.09.2013Hematol Oncol Clin North Am 2013; 27:1243-60, ix
Pezaro Carmel, Omlin Aurelius, Lorente David, de Bono Johann
Neuroonkologie – ASCO 2013: Erst- und Rezidivbehandlung von Glioblastomen – Ernüchterung durch negative Phase-III-Studien
Hundsberger T (2013). Neuroonkologie – ASCO 2013: Erst- und Rezidivbehandlung von Glioblastomen – Ernüchterung durch negative Phase-III-Studien.
19.09.2013Neuroonkologie – ASCO 2013: Erst- und Rezidivbehandlung von Glioblastomen – Ernüchterung durch negative Phase-III-Studien
19.09.2013-
Hundsberger Thomas
Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells
Auner H, Karadimitris A, Apperley J, Rahemtulla A, Dazzi F, Cenci S, Driessen C, Chaidos A, May P, Milan E, Kraus M, Ward T, Moody A, Dillon N. Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. PloS one 2013; 8:e74415.
17.09.2013Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells
17.09.2013PloS one 2013; 8:e74415
Auner Holger W, Karadimitris Anastasios, Apperley Jane F, Rahemtulla Amin, Dazzi Francesco, Cenci Simone, Driessen Christoph, Chaidos Aristeidis, May Philippa, Milan Enrico, Kraus Marianne, Ward Theresa H, Moody Anne Marie, Dillon Niall
Posterior reversible encephalopathy syndrome during induction chemotherapy for acute myeloid leukaemia
Silzle T, Glaser-Gallion N, Hitz F. Posterior reversible encephalopathy syndrome during induction chemotherapy for acute myeloid leukaemia. Eur J Haematol 2013; 92:90.
17.09.2013Posterior reversible encephalopathy syndrome during induction chemotherapy for acute myeloid leukaemia
17.09.2013Eur J Haematol 2013; 92:90
Silzle Tobias, Glaser-Gallion Nicola, Hitz Felicitas
Medulläres Schilddrüsenkarzinom – Eine eigene Entität
Siano M. Medulläres Schilddrüsenkarzinom – Eine eigene Entität. info@onkologie 2013 2013; 3:37-39.
16.09.2013Medulläres Schilddrüsenkarzinom – Eine eigene Entität
16.09.2013info@onkologie 2013 2013; 3:37-39
Siano Marco
CECOG experts’ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer
Siano M. CECOG experts’ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. memo 2013; 6:75-82.
16.09.2013CECOG experts’ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer
16.09.2013memo 2013; 6:75-82
Siano Marco
EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
Baty F, Brutsche M, Pless M, Zappa F, Crowe S, Bubendorf L, Gautschi O, Rauch D, Cathomas R, Dröge C, Betticher D, Früh M, Rothschild S, Swiss Group for Clinical Cancer Research. EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PloS one 2013; 8:e72966.
10.09.2013EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
10.09.2013PloS one 2013; 8:e72966
Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Crowe Susanne, Bubendorf Lukas, Gautschi Oliver, Rauch Daniel, Cathomas Richard, Dröge Cornelia, Betticher Daniel, Früh Martin, Rothschild Sacha, Swiss Group for Clinical Cancer Research
Spirituelle Erfahrung Sterbender
Renz M (2013). Spirituelle Erfahrung Sterbender - Das Ich stirbt in ein Du hinein. Präsentiert bei: Non_Local, Cortona (Italien)
07.09.2013Spirituelle Erfahrung Sterbender
07.09.2013Non_Local
Renz Monika
Response-guided neoadjuvant chemotherapy for breast cancer
von Minckwitz G, Mehta K, Zahm D, Untch M, Schneeweiss A, Paepke S, Kümmel S, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B, Eiermann W, Eidtmann H, Denkert C, Costa S, Blohmer J, Loibl S. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013; 31:3623-30.
03.09.2013Response-guided neoadjuvant chemotherapy for breast cancer
03.09.2013J Clin Oncol 2013; 31:3623-30
von Minckwitz Gunter, Mehta Keyur, Zahm Dirk Michael, Untch Michael, Schneeweiss Andreas, Paepke Stefan, Kümmel Sherko, Kaufmann Manfred, Jackisch Christian, Huober Jens, Hilfrich Jörn, Hanusch Claus, Gerber Bernd, Eiermann Wolfgang, Eidtmann Holger, Denkert Carsten, Costa Serban Dan, Blohmer Jens Uwe, Loibl Sibylle